A strategy to improve use and management of immunoglobulin
At its meeting on 14 March 2019, the Jurisdictional Blood Committee endorsed the National Immunoglobulin Governance Program Performance Improvement Strategy 2019-2022 (the Strategy). This document describes a strategy to improve the prescription, use and management of government-funded Ig products accessed in accordance with the National Policy: Access to Government Funded Immunoglobulin Products in Australia. It has been developed to communicate the intended approach to enhance various aspects of the National Immunoglobulin Governance Program and improve performance through focussed activities. Five pathways are described in this document, each comprising projects and activities which will be implemented in an effort to meet objectives in five performance areas.
The 5 key performance management areas which set the objectives for this strategy are:
- Provision of Ig reflects appropriate clinical practice
- Uniform compliance with the National Policy
- Local Ig governance arrangements are robust and align with relevant standards, guidelines and legislative requirements
- Service delivery provided to support appropriate management and use of Ig (by the NBA and agencies contracted by the NBA) is efficient and effective
- Collection of data supports future work
The pathways that will drive improvement across the performance areas listed above are:
- Education and Support
- Communications and Relationships
- Program Assurance and Policy Compliance
- Knowledge Development
- Enhancement of Policy and Access Arrangements
The approach outlined in this document will further strengthen governance, drive improvement in the prescription, use and management of government-funded Ig products and support the program to continue to deliver against agreed objectives over the coming years.
The Strategy promotes a nationally consistent approach to monitoring performance and identifying obstacles and challenges to performance. As part of the Strategy, the NBA will develop tools and mechanisms to promote continuous improvement amongst all those involved in the prescription, management and use of government-funded Ig products. Where issues are identified, the NBA will develop and implement solutions.
Keep up to date
Ig Program Updates provides a snapshot of the NBA’s current work program and priorities in the immunoglobulin space. It is updated quarterly.
To receive the latest Immunoglobulin Governance Program Updates by email, join the Ig Updates and National Immunoglobulin Interest Group (NIIG) subscription list: email Iggovernance@blood.gov.au(link sends e-mail) with the words SUBSCRIBE Ig Program Updates and NIIG in the subject line.
In the body of the email, please indicate your interest (e.g. Healthcare Professional/ Patient/ Government, etc.) and include your signature block.
Subscribers receive notification of the quarterly Ig Program Updates, and may also be invited to informally discuss and comment on individual Ig-related issues as they arise (participation is optional).
For more information on NIIG, see: www.blood.gov.au/Ig-committees.
For further information
Please contact the National Blood Authority on 13 000 BLOOD (13 000 25 663) or email IgGovernance@blood.gov.au.